On August 1st, Altria Group released its financial report for the second quarter and first half of 2023.
Shipment volume declines, promotional investment increases, resulting in a decrease of 1.7% in net income.
In the first half of 2023, Altria Group reported a net income of $12.23 billion, representing a 1.7% decrease compared to the previous year. However, when excluding consumer taxes, the company's revenue saw a slight growth of 0.1%, amounting to $10.2 billion. Altria stated in a press release that the decline in net income can be attributed to a decrease in shipping volume and increased investments in promotions, although some of these effects were offset by pricing increases.
In the second quarter of 2023, Altria reported a net income of $6.51 billion, representing a decrease of 0.5% compared to the previous year. After excluding sales tax, the company's revenue stood at $5.43 billion, marking a growth of 1.2% year-on-year. Altria stated in a press release that the decline in net income for the second quarter was mainly attributed to a decrease in shipment volume and increased investment in promotions, partially offset by price increases.
Net revenue from oral tobacco products rose by 2.3%, while shipments of nicotine pouches such as ON! saw a significant increase of over 40%.
In the second quarter and first half of 2023, Altria's net revenue from oral tobacco products increased by 2.3%. This growth was primarily driven by price increases, but partially offset by increased promotional investments, reduced shipment volume, and increased on! shipment volume.
In the second quarter and first half of 2023, the shipment volumes of oral tobacco products saw a decline of 1.7% and 1.8% respectively. Among them, the shipment volume of nicotine pouch ON! in the second quarter of 2023 reached 30 million cans, showing a year-on-year increase of 47.8%; for the first half of the year, it reached 55 million cans, with a year-on-year growth of 43%.
In the second quarter and first half of 2023, Altria had a market share of 44% and 44.6% respectively in the oral tobacco products segment.
Philip Morris International (PMI) has successfully completed the acquisition of NJOY and has received a final payment of $1.8 billion.
In a press release, Altria announced that it has successfully completed the acquisition of NJOY Holdings, Inc. on June 1, 2023, by paying a cash amount of $2.75 billion. Additionally, there is a potential for an additional cash payment of up to $500 million in the future, subject to FDA authorization for certain NJOY products.
In July, Altria received a final payment of approximately $1.8 billion (including interest) from Philip Morris International (PMI) as part of the $2.7 billion (including interest) transition agreement for the IQOS tobacco heating system. The proceeds were subsequently used to fully repay the outstanding $2 billion term loan.
Altria's CEO, Billy Gifford, stated, "We had a good performance in the first half of the year and continue to make progress towards our smoke-free goals. We completed the acquisition of NJOY and achieved strong business results, with a 5% increase in adjusted diluted earnings per share for the first half of the year. Additionally, we returned $3.8 billion to shareholders while investing in pursuit of our vision.
We look forward to implementing our business plan for NJOY in the second half of the year, and reiterate our guidance of projected diluted earnings per share in the range of $4.89 to $5.03 for the full year of 2023. This range represents a growth rate of adjusted diluted earnings per share of 1% to 4% from the base of $4.84 in 2022.
Reference:
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
